【加科思-B(01167.HK)：SHP2抑制剂SITNEPROTAFIB联用研究数据发表于学术期刊】加科思-B(01167.HK)发布公告，公司自主研发的SHP2抑制剂sitneprotafib (JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》)。文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有回应的代表性患者病例。

金融界

昨天

加科思-B(01167.HK)发布公告，公司自主研发的SHP2抑制剂sitneprotafib (JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》)。文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有回应的代表性患者病例。

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2534119680"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2534119680\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2534119680?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-05-09 06:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534119680","market":"hk","top_or_hot":-1,"title":"【加科思-B(01167.HK)：SHP2抑制剂SITNEPROTAFIB联用研究数据发表于学术期刊】加科思-B(01167.HK)发布公告，公司自主研发的SHP2抑制剂sitneprotafib (JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》)。文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有回应的代表性患者病例。","media":"金融界","content":"<html><body><div><a href=\"https://laohu8.com/S/01167\">加科思-B</a>(01167.HK)发布公告，公司自主研发的SHP2抑制剂sitneprotafib (JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》)。文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有回应的代表性患者病例。</div></body></html>","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【加科思-B(01167.HK)：SHP2抑制剂SITNEPROTAFIB联用研究数据发表于学术期刊】加科思-B(01167.HK)发布公告，公司自主研发的SHP2抑制剂sitneprotafib (JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》)。文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有回应的代表性患者病例。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【加科思-B(01167.HK)：SHP2抑制剂SITNEPROTAFIB联用研究数据发表于学术期刊】加科思-B(01167.HK)发布公告，公司自主研发的SHP2抑制剂sitneprotafib (JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》)。文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有回应的代表性患者病例。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-09 06:46 北京时间&nbsp;&nbsp;&nbsp;<a href=https://24h.jrj.com.cn/2025/05/09064650243257.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>加科思-B(01167.HK)发布公告，公司自主研发的SHP2抑制剂sitneprotafib (JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》)。文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有回应的代表性患者病例。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/05/09064650243257.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/05/09064650243257.shtml","article_id":"2534119680","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534119680","pubTimestamp":1746744399,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"加科思-B(01167.HK)发布公告，公司自主研发的SHP2抑制剂sitneprotafib (JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》)。文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有回应的代表性患者病例。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4023":"应用软件","PD":"PagerDuty, Inc.","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","01167":"加科思-B"},"translate_title":"[Garcos-B (01167. HK): SHP2 inhibitor sitneprotafib combination research data published in academic journals] Garcos-B (01167. HK) announced that the company's self-developed SHP2 inhibitor sitneprotafib (JAB-3312) related research is published in Clinical Cancer Research (\"Clinical Oncology Research\"). The article announced preclinical in vitro and in vivo data in combination therapies of SHP2 inhibitors and PD-1 antibodies and targeting RTK/RAS/MAPK pathways and representative patient cases who responded to combination therapies.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1,"PD":1},"content_text":"加科思-B(01167.HK)发布公告，公司自主研发的SHP2抑制剂sitneprotafib (JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》)。文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有回应的代表性患者病例。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}